RT Journal Article
SR Electronic
T1 Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.06.20032334
DO 10.1101/2020.03.06.20032334
A1 Broughton, James P.
A1 Deng, Xianding
A1 Yu, Guixia
A1 Fasching, Clare L.
A1 Singh, Jasmeet
A1 Streithorst, Jessica
A1 Granados, Andrea
A1 Sotomayor-Gonzalez, Alicia
A1 Zorn, Kelsey
A1 Gopez, Allan
A1 Hsu, Elaine
A1 Gu, Wei
A1 Miller, Steve
A1 Pan, Chao-Yang
A1 Guevara, Hugo
A1 Wadford, Debra A.
A1 Chen, Janice S.
A1 Chiu, Charles Y.
YR 2020
UL http://medrxiv.org/content/early/2020/03/27/2020.03.06.20032334.abstract
AB An outbreak of novel betacoronavirus, SARS-CoV-2 (formerly named 2019-nCoV), began in Wuhan, China in December 2019 and the COVID-19 disease associated with infection has since spread rapidly to multiple countries. Here we report the development of SARS-CoV-2 DETECTR, a rapid (∼30 min), low-cost, and accurate CRISPR-Cas12 based lateral flow assay for detection of SARS-CoV-2 from respiratory swab RNA extracts. We validated this method using contrived reference samples and clinical samples from infected US patients and demonstrated comparable performance to the US CDC SARS-CoV-2 real-time RT-PCR assay.Competing Interest StatementCYC is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC), receives research support funding from Abbott Laboratories, and is on the Scientific Advisory Board of Mammoth Biosciences, Inc. JSC is a co-founder of Mammoth Biosciences, Inc. JPB, CLF, and JS are employees of Mammoth Biosciences, Inc. CYC, JPB, XD, CLF, JS and JSC are co-inventors of CRISPR-related technologies.Clinical Protocols https://mammoth.bio/2020/02/15/white-paper-a-protocol-for-rapid-detection-of-sars-cov-2-using-crispr-sars-cov-2-detectr/ Funding StatementThis work was funded by NIH grants R33-AI129455 (CYC) from the National Institute of Allergy and Infectious Diseases and R01-HL105704 (CYC) from the National Heart, Lung, and Blood Institute.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe protocol has been released as a white paper online. Any additional data not in the paper can be provided by the authors upon request.